Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lipocine (LPCN) Equity Average (2016 - 2025)

Lipocine (LPCN) has disclosed Equity Average for 13 consecutive years, with $15.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Average fell 22.45% year-over-year to $15.6 million, compared with a TTM value of $15.6 million through Sep 2025, down 22.45%, and an annual FY2024 reading of $20.7 million, down 26.14% over the prior year.
  • Equity Average was $15.6 million for Q3 2025 at Lipocine, down from $18.2 million in the prior quarter.
  • Across five years, Equity Average topped out at $44.0 million in Q1 2022 and bottomed at $15.6 million in Q3 2025.
  • Average Equity Average over 5 years is $29.0 million, with a median of $28.9 million recorded in 2021.
  • The sharpest move saw Equity Average skyrocketed 349.61% in 2021, then tumbled 41.53% in 2023.
  • Year by year, Equity Average stood at $39.2 million in 2021, then decreased by 6.5% to $36.6 million in 2022, then crashed by 41.53% to $21.4 million in 2023, then dropped by 6.39% to $20.1 million in 2024, then decreased by 22.05% to $15.6 million in 2025.
  • Business Quant data shows Equity Average for LPCN at $15.6 million in Q3 2025, $18.2 million in Q2 2025, and $20.1 million in Q1 2025.